Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer

NCT02987829 is registered in ClinicalTrials.gov with Tracon Pharmaceuticals Inc. as lead sponsor.

NCT NCT02987829
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02987829 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label Phase 1/2A Study To Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of TRC253, an Androgen Receptor Antagonist, in Patients With Metastatic Castration-resistant Prostate Cancer
Lead sponsor
Tracon Pharmaceuticals Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
May 23, 2017
Completion date
November 9, 2020
Enrollment
72 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adenocarcinoma, prostate, metastatic castrate-resistant prostate cancer